The publication of the Renewed Women’s Health Strategy for England signals a pivot from the government in how women’s health services are designed, delivered and evaluated across the NHS.  For a workforce embedded in clinical decision-making, prevention and patient engagement, the strategy represents both a challenge and an opportunity for the pharmacy sector to reshape how care is delivered for women.

At its core, the strategy responds to persistent inequalities in women’s health outcomes, including stark variations linked to deprivation, ethnicity and access to care. The strategy highlights how women continue to spend a greater proportion of their lives in ill health compared to men, and those in the most deprived communities experience significantly worse outcomes. The strategy acknowledges that women’s concerns have historically been “dismissed or not taken seriously”, leading to delays in diagnosis and treatment. This spotlights the need for more targeted, proactive interventions. For pharmacy professionals, this reinforces the importance of addressing health inequalities through personalised care, culturally competent communication and equitable access to medicines and services.

A defining feature of the renewed strategy is its emphasis on placing women’s voices and experiences at the centre of healthcare delivery. This includes new mechanisms to capture patient feedback and, notably, proposals to link this feedback to provider funding and service improvement. This marks a shift towards greater accountability for patient experience, requiring a more holistic approach to consultations, shared decision-making and follow-up. Medicines-related discussions, whether around contraception, menopause management or long-term conditions, will increasingly need to reflect individual preferences, experiences and outcomes. This aligns closely with the wider NHS direction of travel as outlined in the 10-Year Health Plan. 

Another key priority is improving access and reducing delays in diagnosis and treatment, particularly in areas where women experience long waits or fragmented care, such as with gynaecological conditions, where waiting times have historically been long. The introduction of streamlined referral pathways and enhanced community-based services aims to ensure patients are directed to the right professional at the right time.

What does all this mean in practice for pharmacy professionals? In primary care, pharmacy professionals are likely to play a more prominent role in managing menopause, menstrual health and chronic diseases through structured medication reviews, independent prescribing and integrated care pathways. Pharmacy professionals are well placed to support early identification of symptoms, provide initial management, and facilitate timely referral, thereby helping to reduce system pressures and improve outcomes for patients. In hospital settings, there is an opportunity to strengthen transitions of care, ensuring that women receive consistent, optimised treatment across the care continuum.

The strategy also reinforces the NHS shift towards prevention and earlier intervention. It emphasises the need to “improve access to information, prevention and early diagnosis across the life course.” For example, in primary care, pharmacy professionals can proactively identify women at risk of certain health concerns, through hypertension case-finding, lipid management or contraceptive consultations, and intervening earlier with prescribing or referral. In secondary care, it means embedding preventative thinking into routine care pathways, such as initiating bone protection in at-risk women or addressing cardiovascular risk factors during unrelated admissions.

Finally, the strategy highlights the need for a more joined-up, system-wide approach. There is a clear opportunity to develop pharmacy-led pathways, for example, structured menopause services, cardiovascular risk clinics targeting women, or medicines optimisation programmes that address polypharmacy in older women. It also requires stronger collaboration across sectors to ensure consistent messaging and care transitions.

Ultimately, the renewed women’s health strategy is underscored by the growing expectation that pharmacy teams will contribute not only to safe and effective medicines use, but also to reducing inequalities and improving access. This evolving policy landscape demands leadership, innovation and a willingness to embed women’s health as a core component of everyday clinical practice to deliver measurable improvements in outcomes and experience.